These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 38264122)
1. Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment. Rahban M; Joushi S; Bashiri H; Saso L; Sheibani V Front Chem; 2023; 11():1325214. PubMed ID: 38264122 [TBL] [Abstract][Full Text] [Related]
2. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma. Nakada M; Kita D; Watanabe T; Hayashi Y; Hamada J Brain Tumor Pathol; 2014 Jul; 31(3):198-207. PubMed ID: 24399202 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Brar HK; Jose J; Wu Z; Sharma M Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter? Aldaz P; Arozarena I Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830952 [TBL] [Abstract][Full Text] [Related]
5. Small molecule tyrosine kinase inhibitors in glioblastoma. Kim G; Ko YT Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429 [TBL] [Abstract][Full Text] [Related]
6. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma. Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860 [TBL] [Abstract][Full Text] [Related]
7. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Raizer JJ J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112 [TBL] [Abstract][Full Text] [Related]
8. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Verdugo E; Puerto I; Medina MÁ Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048 [TBL] [Abstract][Full Text] [Related]
9. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812 [TBL] [Abstract][Full Text] [Related]
10. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
11. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724 [TBL] [Abstract][Full Text] [Related]